DocWire News Editors

DocwireNews

Several researchers discussed polypoidal choroidal vasculopathy (PCV) during AAO 2019.In one scientific poster presentation, &ldquo;Automated Classification of Polypoidal Choroidal Vasculopathy and Other Subtypes of AMD Using Bimodal Deep Convolutional Neural Networks,&rdquo; the authors of this retrospective study utilized a bimodality deep convolutional neural network (DCNN) to recognize PCV and other age-related macular degeneration (AMD) subtypes using color fundus and optical coherence tomography (OCT). Between 2013 and 2018, 904 AMD and PCV patients and 195 controls were assessed; 2,389 anonymous fundus and OCT images were evaluated, all of which were pre-categorized into four groups: normal, dry AMD, wet AMD, or PCV. Additional comparisons were drawn using unimodal DCNN-OCT/Fundus and bimodal DCNN-Combo. The researchers employed a human-machine comparison. Final analysis included 223 images from 80 years (20 eyes per group). DCNN-Combo outperformed the other techniques, with an accuracy of 87.4%, sensitivity of 88.8% and specificity of 95.6%. DCNN-Combo performed slightly better than the best expert (Machine &kappa;, 0.828; Human1 &kappa;, 0.810).In a second scientific poster presentation, &ldquo;Evolution of Polypoidal Lesions Among Patients of a Multicenter Randomized Controlled Clinical Trial on Polypoidal Choroidal Vasculopathy,&rdquo; researchers examined polyp evolution in symptomatic macular PCV patients and assessed differences between baseline and new polyps. This randomized, controlled, multicenter trial included 30 patients whose indocyanine green angiograms (ICGAs) were reviewed at baseline and again after three, six, 12, and 24 months. A reading center was used to determine polyp evaluation and how it was associated with treatment. Patients treated with combination photodynamic therapy and ranibizumab had significantly higher complete polyp regression than patients receiving ranibizumab monotherapy (80.0% vs. 35.7% at 12 months; P=0.016). The combination therapy group also had lower persistent baseline polyps than the monotherapy group (6.7% vs. 50.0%; P&lt;0.001). Most new polyps developed from month six and continued to form a more significant proportion of all polyps over the duration of treatment.

Jordana Jampel

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Andrew Moreno

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Katie Kosko

EMBER-3: Imlunestrant Plus Abemaciclib Improves PFS in ER+ Breast Cancer

HR Breast Cancer

Latest News

Polypoidal Choroidal Vasculopathy: Polyp Evolution, Disease Classification

Ophthalmology

Several researchers discussed polypoidal choroidal vasculopathy (PCV) during AAO 2019. ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe